Biotechnology

Quoin Pharmaceuticals

Quoin Pharmaceuticals released FY2026 Q1 earnings on May 7 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -1.8)

Quoin Pharmaceuticals to Release FY2026 Q1 Earnings on May 7, Pre-Market EST, Forecast EPS USD -1.76

Quoin Pharmaceuticals released FY2025 annual earnings on March 26, 2026, pre-market EST: Actual Revenue USD 0, Actual EPS USD -14.7962 (Forecast EPS USD -20.155)

Quoin Pharmaceuticals released FY2025 Q4 earnings on March 26 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -61.0178 (forecast USD -4.02)

Quoin Pharmaceuticals to Release FY2025 Q4 Earnings on March 26, Pre-Market EST, Forecast EPS USD -4.02

Quoin Pharmaceuticals released FY2025 9 Months Earnings on November 6 Pre-Market EST, with actual revenue of USD 0 and EPS of USD -19.5217

Quoin Pharmaceuticals released FY2025 Q3 earnings on November 6 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -6.72 (forecast USD -6.36)

Quoin Pharmaceuticals to Release FY2025 Q3 Earnings on November 6, 2025 Pre-Market EST, Forecast EPS USD -6.36

Director Dennis Langer Buys Quoin Pharmaceuticals Stock

Quoin Pharmaceuticals Ltd. Conducts Up to $104.5 Million Private Placement Financing

Quoin Pharmaceuticals released FY2025 Semi-Annual earnings on August 7 Pre-Market (EST), actual revenue USD 0, actual EPS USD -12.9499

Quoin Pharmaceuticals released FY2025 Q2 earnings on August 7 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -219.93 (forecast USD -6.83)

Quoin Pharmaceuticals to Release FY2025 Q2 Earnings on August 7, Pre-Market EST, Forecast EPS USD -6.82

Quoin Pharmaceuticals' QRX003 Receives FDA Rare Pediatric Disease Designation

Quoin Pharmaceuticals Granted FDA Approval for Phase 2 Key Clinical Trial

Quoin Pharmaceuticals (QNRX) Receives Orphan Drug Designation for QRX003

Quoin Pharmaceuticals released FY2025 Q1 earnings on May 13 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -6.5017 (forecast USD -3.85)

Quoin Pharmaceuticals to release FY2025 Q1 earnings report on May 13 Pre-Market EST, forecast EPS USD -3.85

Quoin Pharmaceuticals Announces Positive Clinical Data from Children's Netherton Syndrome Study and Receives Approval to Test Second Patient

Quoin Pharmaceuticals Applies for Patent for New Topical Formulation to Treat Netherton Syndrome in the US

Meiwu Tech

Amesite

InMed Pharmaceuticals

Generation Income Properties

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Co-Diagnostics

MetaVia

Phoenix Asia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

Gen Digital - Rights

BCRX

QNRX

LABU

IBBQ

ARKG

The Netherton syndrome market is projected to grow from 2026 to 2036, driven by new therapies like QRX003, BCX17725, and ATR-12. The U.S. is expected to lead in market size, with an increase in diagnosed cases due to better diagnostics. Current treatments are mainly symptomatic, highlighting the need for effective, targeted therapies. The development of these new drugs presents significant opportunities in addressing the unmet medical needs of Netherton syndrome patients.

prnewswire

BioCryst Pharma

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

iShares Global Healthcare

VG Health

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Azitra

QUOIN PHARMACEUTICALS LTD SPON ADS EACH REP 1 ORD SHS

06:31 ETNetherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight

Maxim Group analyst Naz Rahman has reiterated a Buy rating on Quoin Pharmaceuticals (QNRX) with a price target of $40.00. Alliance Global Partners also maintains a Buy rating with a $35.00 target. Rahman focuses on the Healthcare sector and has an average return of -9.6% with a 35.83% success rate on his stock recommendations.

Tip Ranks

Vertex Pharma

Silexion Therapeutics

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM)

Quoin Pharmaceuticals (QNRX) Receives a Buy from Maxim Group

Earnings Watch

Quoin Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0

Quoin Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0

CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs | QNRX Stock News

StockTitan

CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs | QNRX Stock News

Quoin Pharmaceuticals Ltd (QNRX) has revealed increased financing risks due to covenants in its October 2025 Purchase Agreement, which restrict variable rate financings until April 2026 and equity financings below the unit price until June 2026. These limitations, along with a 25% participation right for October Purchasers, may hinder the company's ability to secure necessary funding, leading to potential program delays or terminations that could adversely affect its business. The average stock price target for QNRX is $37.50, indicating a potential upside of 485.02%.

Financing Covenants Put Quoin Pharmaceuticals at Heightened Risk of Funding Shortfall and Program Delays

Quoin Pharmaceuticals fell 14.08%; AbbVie fell 0.68%, with a trading volume of USD 672 million; Forte Pharma fell 4.39%, with a trading volume of USD 537 million; Amgen fell 1.24%, with a trading volume of USD 450 million; Gilead Sciences fell 1.69%, with a market value of USD 167 billion

Price Alert

U.S. stock market update: Quoin Pharmaceuticals down 14.08%, cash flow crisis and FDA meeting fail to boost market confidence

RCKT

In Friday's pre-market session, several health care stocks experienced notable movements. Pomdoctor (POM) shares surged 33% to $0.36, while OnKure Therapeutics (OKUR) rose 19.17% to $5.47. Other gainers included GlucoTrack (GCTK) up 17.42% to $1.28, Lantern Pharma (LTRN) up 12.44% to $2.35, and Rocket Pharmaceuticals (RCKT) up 11.3% to $5.22. Conversely, ENDRA Life Sciences (NDRA) fell 12.4% to $4.02, Universe Pharmaceuticals (UPC) dropped 10.26% to $2.1, and Acumen Pharmaceuticals (ABOS) declined 10.2% to $2.29. Quoin Pharmaceuticals (QNRX) and Zenas BioPharma (ZBIO) also saw declines following their Q4 earnings reports.

Quoin Pharmaceuticals(QNRX.US)

06:31 ETNetherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight

Quoin Pharmaceuticals (QNRX) Receives a Buy from Maxim Group

Quoin Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0

Quoin Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0

CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs | QNRX Stock News

Financing Covenants Put Quoin Pharmaceuticals at Heightened Risk of Funding Shortfall and Program Delays

U.S. stock market update: Quoin Pharmaceuticals down 14.08%, cash flow crisis and FDA meeting fail to boost market confidence

12 Health Care Stocks Moving In Friday's Pre-Market Session